RCE1 Inhibitors

Chemical inhibitors of RCE1 can exert their inhibitory effects through various mechanisms that ultimately reduce the availability of the protein's substrates or interfere with its enzymatic function. Palmostatin B directly targets RCE1 by obstructing its depalmitoylating activity, resulting in an accumulation of improperly processed palmitoylated proteins and thus impeding RCE1's ability to carry out its normal biological functions. Similarly, other inhibitors affect the upstream processes that supply substrates for RCE1. Tipifarnib and Lonafarnib, both farnesyltransferase inhibitors, limit the pool of farnesylated proteins that RCE1 would typically modify. By doing so, these chemicals ensure that the proteins meant for RCE1-mediated processing are not appropriately prenylated, thereby preventing RCE1 from acting on these substrates.

Moreover, Manumycin A, Zoledronic acid, Perillyl alcohol, D-Limonene, and the peptidomimetic FTI-277 also target farnesyltransferase, leading to a similar decrease in the farnesylation of proteins. This depletion of farnesylated proteins available for RCE1 results in the functional inhibition of RCE1's role in the post-translational modification of these proteins. GGTI-298, while inhibiting geranylgeranyltransferase I, causes an alteration in the spectrum of prenylated proteins, which can indirectly influence the activity of RCE1 by affecting the availability of its substrates. L-744832 further supports this approach by inhibiting farnesyltransferase and thus, indirectly impeding RCE1 activity. Additionally, natural compounds like (-)-Epigallocatechin gallate (EGCG) and Quercetin also exhibit inhibitory activity against farnesyltransferase, which in turn reduces the substrate pool for RCE1, leading to an indirect inhibition of its functional role in protein processing.